NGEN (NervGen Pharma) Marketable Securities: $0.00 Mil (As of Mar. 2026)


NGEN NervGen Pharma Corp NGEN
22 GF Score
Price $1.85
! 2 Warning Signs
View Full Analysis

What is NervGen Pharma Marketable Securities?

NervGen Pharma NGEN -7.50% 22 Marketable Securities is $0.00 Mil as of Mar. 2026. GuruFocus rates NGEN with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. NervGen Pharma's Marketable Securities for the quarter that ended in Mar. 2026 was $0.00 Mil.

NervGen Pharma's annual Marketable Securities increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.07 Mil) but then declined from Dec. 2024 ($0.07 Mil) to Dec. 2025 ($0.01 Mil).

NervGen Pharma  (NAS:NGEN) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

NervGen Pharma Marketable Securities Related Terms

NervGen Pharma Marketable Securities Historical Data

* Premium members only.

The historical data trend for NervGen Pharma's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NervGen Pharma Marketable Securities Chart

NervGen Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.07 0.01

NervGen Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.04 0.02 0.01 0.00
NGEN
22GF Score
NervGen Pharma Corp NGEN
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NervGen Pharma Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.00 Mil mean?
NervGen Pharma (NGEN) has a Marketable Securities of $0.00 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on NervGen Pharma and its competitors.
Is NervGen Pharma's Marketable Securities too high?
NervGen Pharma's current Marketable Securities is $0.00 Mil. Overall, NervGen Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does NervGen Pharma's Marketable Securities compare to NKTX and UNCY?
NervGen Pharma's Marketable Securities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on NervGen Pharma and its competitors. NervGen Pharma's current Marketable Securities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NervGen Pharma stock overvalued right now?
NervGen Pharma (NGEN) has a current Marketable Securities of $0.00 Mil. The current Marketable Securities is $0.00 Mil. NervGen Pharma's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For NervGen Pharma (NGEN), the current Marketable Securities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NervGen Pharma Business Description

Other Exchanges 9UA:Germany
Address 112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
22GF Score

Get the complete analysis for NGEN

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.85
Price